The revenue miss and GAAP net loss driven by investment mark-to-market are the headline negatives, but operating income grew 22% and IST product sales accelerated 45% YoY. Watch for Q4 revenue trajectory and whether NUZOLVENCE adoption can offset continued royalty erosion from GSK.
Drugs in focus
INVA drug pipeline →GIAPREZA
● Neutral Named in this 8-K- Impact
- Phase
- Approved
- Time to market
- Already approved and commercially available (FDA approved December 2017).
- Next catalyst
- None dated
What to watchGIAPREZA has no upcoming FDA decision or pivotal readout; the next catalyst for Innoviva is the Q4 2026 earnings report (likely February 2027), where GIAPREZA's continued sales growth trajectory will be the key metric to watch. The drug's $23.1M quarterly run rate is on pace to help Innoviva hit its at-least-$150M full-year IST product sales guidance.
How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 5 $19.24entry
- T+1 · 11d ago −0.73%α −1.04% · $19.10
- T+5 · 5d ago −1.40%α −4.69% · $18.97
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Innoviva Q3 2026 total revenue of $106.1M declined 1.6% YoY, missing the $115.3M consensus, as lower royalty revenue and ex-U.S. timing offset 45% growth in U.S. IST net product sales to $43.3M. GAAP net loss of $73.9M ($1.03 basic loss) was driven by a $139.5M unfavorable fair-value change in equity investments, primarily Armata Pharmaceuticals. The company maintained its 2026 U.S. IST sales guidance of at least $150M and repurchased 1.2M shares for $26.3M in Q3.
Key Financial Metrics
Key Facts
- Total revenue $106.1M, down 1.6% YoY from $107.8M, missing $115.3M consensus
- GAAP net loss of $73.9M ($1.03 basic loss) vs net income of $89.9M ($1.30 basic) in Q3 2025
- U.S. IST net product sales $43.3M, up 45% YoY from $29.9M
- Gross royalty revenue from GSK stable at $58.1M vs $63.4M in Q3 2025
- Income from operations $42.2M, up 21.9% YoY from $34.6M
- Net unfavorable fair-value changes in equity/long-term investments totaled $139.5M
- Cash and cash equivalents $581.4M at Sept 30, 2026
- Repurchased 1,226,948 shares for $26.3M in Q3; $82.7M total under $125M buyback program
- NUZOLVENCE now commercially available in the U.S.
- Maintained 2026 guidance of at least $150M in U.S. net product sales
Financial Impact
Revenue miss of ~$9.2M vs consensus; GAAP net loss of $73.9M vs prior-year net income of $89.9M; operating income grew 21.9% to $42.2M
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Royalty revenue, net | $54.7M | -8.8% |
| Net product sales | $49.4M | +4.5% |
| License and other revenue | $2.0M | +231.0% |
Risk Factors
- Total revenue declined YoY and missed consensus, driven by lower GSK royalty revenue and ex-U.S. timing
- GAAP net loss of $73.9M from $139.5M unfavorable fair-value changes in equity investments, primarily Armata Pharmaceuticals
- Royalty revenue from GSK declining: gross royalties $58.1M vs $63.4M in Q3 2025
- Selling, general and administrative expenses increased 35.6% YoY to $37.0M
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-447366 |
| Document: d177079d8k.htm | 0001193125-26-447366 |
| Document: 0001193125-26-447366-index-headers.html | 0001193125-26-447366 |
| Document: 0001193125-26-447366-index.html | 0001193125-26-447366 |
| Document: 0001193125-26-447366.txt | 0001193125-26-447366 |
| 8-K Data (Synthetic) | 0001193125-26-447366 |
Track record
5 reports on INVA
Filters
- Nov 4, 202612d ago 8-K Bearish 5/10 Viewing Entry $19.24 to $18.97 Now $18.49 +3.90% ▲ +1.40% +4.69% vs SPY
- Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $21.12 to $21.26 Now $18.49 −12.45% ▲ +0.66% +1.38% vs SPY
- May 18, 202626w ago 8-K Neutral 3/10 Entry $21.73 to $22.13 Now $18.49 −14.91% ▲ +1.84% −0.46% vs SPY
- May 6, 202627w ago 8-K Mixed 5/10 Entry $22.80 to $23.14 Now $18.49 −18.90% ▲ +1.49% −0.01% vs SPY
- Mar 27, 202633w ago 10-K/A Neutral 3/10 Entry $22.91 to $23.28 Now $18.49 −19.29% ▲ +1.61% −2.69% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers